Bristol Myers Squibb Abecma approved in European Union for triple-class exposed relapsed and refractory multiple myeloma Ruchika Sharma22 March 2024 4:02 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Abecma (idecabtagene vicleucel;...
Bristol Myers Squibb Abecma approved for use in earlier lines of therapy for patients with relapsed or refractory Multiple Myeloma in Japan Ruchika Sharma7 Dec 2023 4:30 PM ISTTokyo: Bristol-Myers Squibb K.K. has announced that the company has received manufacturing and marketing approval of the supplemental New Drug...
US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy Ruchika Sharma21 Nov 2023 2:30 PM ISTThe therapy was originally co-developed by bluebird bio but following its spin-off in 2021 became part of 2seventy's portfolio.
GSK, Sanofi, Pfizer and other drugmakers plan to raise prices on at least 350 drugs in US in January Ruchika Sharma31 Dec 2022 1:15 PM ISTTo date, Pfizer announced the most increases, with prices rising on 89 unique drug brands, and an additional increase on 10 drug brands at its Hospira...
